Eledon Pharmaceuticals, Inc. ELDN 深 滬
等待開盤 06-25 09:30:00 美东时间
3.96
+0.010
+0.25%
華盛通- 最 高4.30
- 今 開4.06
- 成交量 190.91万股
- 最 低 3.85
- 昨 收 3.95
- 總市值 3.06亿
- 52周最高 4.60
- 市盈率 靜 --
- 換手率 2.47%
- 52周最低 1.35
- 委 比 -63.12%
- 總股本 7718.78万
- 歷史最高 154.98
- 量 比 0.81
- 振 幅 11.39%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote
The latest update is out from Eledon Pharmaceuticals ( ($ELDN) ). At its Annual...
06-23 06:47
Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated pat...
06-22 19:15
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW trial for tegoprubart in kidney transplant patients. Results showed sustained kidney function benefits, with a statistically significant 12 mL/min/1.73 m² higher eGFR at 18 months vs. tacrolimus. No biopsy-proven acute rejection (BPAR) events were observed after six months in tegoprubart-treated patients, compared to seven BPAR events in the tacrolimus arm. Patient-report...
06-22 11:00
Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented
06-05 04:33
Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster
05-21 04:16
Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from
05-14 05:32
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals reported its first quarter 2026 results, highlighting significant progress with tegoprubart in kidney and islet cell transplantation, including 100% insulin independence for 10 patients with type 1 diabetes. The FDA granted orphan drug designation for tegoprubart in liver transplantation. Cash and short-term investments totaled $111.1 million as of March 31, 2026. The company also announced plans for multiple clinical trial...
05-13 20:05
Eledon Pharmaceuticals Files Prospectus For Offering $500M Securities
https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
05-02 04:14
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
04-30 20:01
NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that
04-20 19:39
